State Street Corp Sells 47,600 Shares of BioXcel Therapeutics, Inc. (NASDAQ:BTAI)

State Street Corp cut its holdings in shares of BioXcel Therapeutics, Inc. (NASDAQ:BTAI) by 38.2% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 77,149 shares of the company’s stock after selling 47,600 shares during the period. State Street Corp owned about 0.19% of BioXcel Therapeutics worth $47,000 at the end of the most recent quarter.

Other institutional investors have also recently added to or reduced their stakes in the company. Point72 Asia Singapore Pte. Ltd. bought a new stake in shares of BioXcel Therapeutics in the second quarter worth $39,000. XTX Topco Ltd lifted its holdings in BioXcel Therapeutics by 49.0% during the 2nd quarter. XTX Topco Ltd now owns 46,503 shares of the company’s stock worth $60,000 after buying an additional 15,291 shares during the period. Finally, Armistice Capital LLC grew its position in shares of BioXcel Therapeutics by 705.2% in the 2nd quarter. Armistice Capital LLC now owns 2,987,000 shares of the company’s stock valued at $3,823,000 after buying an additional 2,616,027 shares during the last quarter. 30.68% of the stock is owned by institutional investors.

Analysts Set New Price Targets

Separately, HC Wainwright cut their price objective on BioXcel Therapeutics from $7.00 to $5.00 and set a “buy” rating on the stock in a research note on Monday, October 21st.

BioXcel Therapeutics Stock Up 5.6 %

BTAI stock opened at $0.41 on Friday. The firm has a market cap of $17.70 million, a price-to-earnings ratio of -0.19 and a beta of 0.11. The company’s fifty day simple moving average is $0.49 and its 200 day simple moving average is $0.70. BioXcel Therapeutics, Inc. has a 12-month low of $0.30 and a 12-month high of $4.17.

BioXcel Therapeutics Profile

BioXcel Therapeutics, Inc, a commercial-stage biopharmaceutical company, engages in utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology. The company's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices.